High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers

See Hyoung Park, Xiaobing Wang, Ruiwu Liu, Kit Lam, Robert H Weiss

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Kidney cancer is notoriously difficult to treat when metastatic due to its resistance to conventional chemotherapy. p21 is a cyclin kinase inhibitor which, in many tumor cell lines, conveys an antiapoptotic function through its induction by the DNA damage responsive p53 pathway, such that attenuation of p21 sensitizes several disparate cancer cell lines to DNA-damaging chemotherapy. Since clinical applications with therapeutic antisense and siRNA approaches are problematic, we sought to discover other methods to inhibit p21 which are more readily translatable to the clinic. Utilizing an on-bead enzyme-linked colorimetric binding assay, we screened a diverse one-bead-one-compound combinatorial small molecule library, and identified 12 candidate compounds which bind p21. Each of the 12 candidate compounds was synthesized and tested individually, and 3 ligands were found which had the highest p21 binding affinity and yielded similar chemical structure. These 3 compounds caused dose-dependent cytotoxicity as well as apoptosis when exposed to two RCC cell lines. In addition, these compounds sensitized cells to apoptosis when incubated with doxorubicin such that a lower dose of doxorubicin was required in the presence of the compounds for equivalent cell killing. Interestingly, a representative of the 3 compounds decreased p21 levels by specific induction of ubiquitin-dependent proteosome degradation. Thus, by high throughput screening of thousands of candidate small molecules, we have identified compounds which attenuate p21, cause RCC cell apoptosis, and sensitize RCC cells to DNA-damaging chemotherapy. These compounds are currently being evaluated in in vivo assays as potential novel therapeutic for RCC.

Original languageEnglish (US)
Pages (from-to)2015-2022
Number of pages8
JournalCancer Biology and Therapy
Volume7
Issue number12
StatePublished - Dec 2008

Fingerprint

Drug Therapy
Apoptosis
Doxorubicin
Small Molecule Libraries
Cell Line
Cyclins
Kidney Neoplasms
DNA
Ubiquitin
Tumor Cell Line
Small Interfering RNA
DNA Damage
Phosphotransferases
Ligands
Enzymes
Therapeutics
Neoplasms

Keywords

  • Apoptosis
  • Chemotherapy sensitization
  • Combinatorial chemistry
  • Kidney cancer
  • P21

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers. / Park, See Hyoung; Wang, Xiaobing; Liu, Ruiwu; Lam, Kit; Weiss, Robert H.

In: Cancer Biology and Therapy, Vol. 7, No. 12, 12.2008, p. 2015-2022.

Research output: Contribution to journalArticle

@article{40c4f7230b4a4421828307efc92bb604,
title = "High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers",
abstract = "Kidney cancer is notoriously difficult to treat when metastatic due to its resistance to conventional chemotherapy. p21 is a cyclin kinase inhibitor which, in many tumor cell lines, conveys an antiapoptotic function through its induction by the DNA damage responsive p53 pathway, such that attenuation of p21 sensitizes several disparate cancer cell lines to DNA-damaging chemotherapy. Since clinical applications with therapeutic antisense and siRNA approaches are problematic, we sought to discover other methods to inhibit p21 which are more readily translatable to the clinic. Utilizing an on-bead enzyme-linked colorimetric binding assay, we screened a diverse one-bead-one-compound combinatorial small molecule library, and identified 12 candidate compounds which bind p21. Each of the 12 candidate compounds was synthesized and tested individually, and 3 ligands were found which had the highest p21 binding affinity and yielded similar chemical structure. These 3 compounds caused dose-dependent cytotoxicity as well as apoptosis when exposed to two RCC cell lines. In addition, these compounds sensitized cells to apoptosis when incubated with doxorubicin such that a lower dose of doxorubicin was required in the presence of the compounds for equivalent cell killing. Interestingly, a representative of the 3 compounds decreased p21 levels by specific induction of ubiquitin-dependent proteosome degradation. Thus, by high throughput screening of thousands of candidate small molecules, we have identified compounds which attenuate p21, cause RCC cell apoptosis, and sensitize RCC cells to DNA-damaging chemotherapy. These compounds are currently being evaluated in in vivo assays as potential novel therapeutic for RCC.",
keywords = "Apoptosis, Chemotherapy sensitization, Combinatorial chemistry, Kidney cancer, P21",
author = "Park, {See Hyoung} and Xiaobing Wang and Ruiwu Liu and Kit Lam and Weiss, {Robert H}",
year = "2008",
month = "12",
language = "English (US)",
volume = "7",
pages = "2015--2022",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "12",

}

TY - JOUR

T1 - High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers

AU - Park, See Hyoung

AU - Wang, Xiaobing

AU - Liu, Ruiwu

AU - Lam, Kit

AU - Weiss, Robert H

PY - 2008/12

Y1 - 2008/12

N2 - Kidney cancer is notoriously difficult to treat when metastatic due to its resistance to conventional chemotherapy. p21 is a cyclin kinase inhibitor which, in many tumor cell lines, conveys an antiapoptotic function through its induction by the DNA damage responsive p53 pathway, such that attenuation of p21 sensitizes several disparate cancer cell lines to DNA-damaging chemotherapy. Since clinical applications with therapeutic antisense and siRNA approaches are problematic, we sought to discover other methods to inhibit p21 which are more readily translatable to the clinic. Utilizing an on-bead enzyme-linked colorimetric binding assay, we screened a diverse one-bead-one-compound combinatorial small molecule library, and identified 12 candidate compounds which bind p21. Each of the 12 candidate compounds was synthesized and tested individually, and 3 ligands were found which had the highest p21 binding affinity and yielded similar chemical structure. These 3 compounds caused dose-dependent cytotoxicity as well as apoptosis when exposed to two RCC cell lines. In addition, these compounds sensitized cells to apoptosis when incubated with doxorubicin such that a lower dose of doxorubicin was required in the presence of the compounds for equivalent cell killing. Interestingly, a representative of the 3 compounds decreased p21 levels by specific induction of ubiquitin-dependent proteosome degradation. Thus, by high throughput screening of thousands of candidate small molecules, we have identified compounds which attenuate p21, cause RCC cell apoptosis, and sensitize RCC cells to DNA-damaging chemotherapy. These compounds are currently being evaluated in in vivo assays as potential novel therapeutic for RCC.

AB - Kidney cancer is notoriously difficult to treat when metastatic due to its resistance to conventional chemotherapy. p21 is a cyclin kinase inhibitor which, in many tumor cell lines, conveys an antiapoptotic function through its induction by the DNA damage responsive p53 pathway, such that attenuation of p21 sensitizes several disparate cancer cell lines to DNA-damaging chemotherapy. Since clinical applications with therapeutic antisense and siRNA approaches are problematic, we sought to discover other methods to inhibit p21 which are more readily translatable to the clinic. Utilizing an on-bead enzyme-linked colorimetric binding assay, we screened a diverse one-bead-one-compound combinatorial small molecule library, and identified 12 candidate compounds which bind p21. Each of the 12 candidate compounds was synthesized and tested individually, and 3 ligands were found which had the highest p21 binding affinity and yielded similar chemical structure. These 3 compounds caused dose-dependent cytotoxicity as well as apoptosis when exposed to two RCC cell lines. In addition, these compounds sensitized cells to apoptosis when incubated with doxorubicin such that a lower dose of doxorubicin was required in the presence of the compounds for equivalent cell killing. Interestingly, a representative of the 3 compounds decreased p21 levels by specific induction of ubiquitin-dependent proteosome degradation. Thus, by high throughput screening of thousands of candidate small molecules, we have identified compounds which attenuate p21, cause RCC cell apoptosis, and sensitize RCC cells to DNA-damaging chemotherapy. These compounds are currently being evaluated in in vivo assays as potential novel therapeutic for RCC.

KW - Apoptosis

KW - Chemotherapy sensitization

KW - Combinatorial chemistry

KW - Kidney cancer

KW - P21

UR - http://www.scopus.com/inward/record.url?scp=58149119381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149119381&partnerID=8YFLogxK

M3 - Article

C2 - 18981726

AN - SCOPUS:58149119381

VL - 7

SP - 2015

EP - 2022

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 12

ER -